| 缩氨基硫脲Ni（Ⅱ）配合物的合成、晶体结构、DNA相互作用及抗肿瘤活性研究 | |
| Synthesis, Crystal Structure, DNA Interaction and Antitumor Activity of Nickel(Ⅱ) Complex with Quinoline-2-carboxaldehyde N4-methyl-thiosemicarbazone | |
| 摘要: 合成了一种缩氨基硫脲Ni髤配合物[Ni（QCMT）2]Cl2·2CH3OH·1.5H2O（QCMT为喹啉-2-甲醛-N4-甲基缩氨基硫脲）。该配合物晶体属于三斜晶系，P1 空间群，a=1.000 2（2） nm，b=1.093 9（2） nm，c=1.583 6（3） nm，α=93.99（3）°，β=105.25（3）°，γ=108.46（3）°。中心离子Ni2+处于变形八面体配位环境中。电子吸收光谱、荧光光谱及圆二色谱分析表明该配合物通过静电作用方式与DNA相结合。测定了该Ni（Ⅱ）配合物与配体（QCMT）对人乳腺癌细胞系MCF-7、人卵巢癌细胞系SKOV-3及人非小细胞肺癌耐顺铂细胞系A-549/CDDP的体外细胞毒活性。结果表明，Ni（Ⅱ）配合物对MCF-7细胞系的细胞毒活性强于顺铂，同时该配合物对MCF-7和SKOV-3两种细胞系的细胞毒活性明显优于其配体。 | |
| 关键词: 镍配合物 缩氨基硫脲 DNA相互作用 细胞毒活性 | |
| 基金项目: 湖南省自然科学基金（No.12JJ3016）资助项目。 | |
| Abstract: A nickel complex,[Ni(QCMT)2]Cl2·2CH3OH·1.5H2O (QCMT=quinoline-2-carboxaldehyde-N4-methyl-thiosemicarbazone), has been synthesized and characterized. The complex crystallized in a tirclinic system with space group P1, a=1.000 2(2) nm, b=1.093 9(2) nm, c=1.583 6(3) nm, α=93.99(3)°, β=105.25(3)°, γ=108.46(3)°. Nickel(Ⅱ) ion is situated in a distorted octahedral geometry. Interaction of the nickel(Ⅱ) complex with calf thymus DNA was investigated by electronic absorption spectra, circular dichroism (CD) spectra and fluorescence spectra. The results suggest that nickel(Ⅱ) complex binds to DNA through a electrostatic binding mode. The in vitro cytotoxicity have been tested against the human breast adenocarcinoma cell line MCF-7, human ovarian carcinoma cell line SKOV-3 and cisplatin-resistant cell line A-549/CDDP. The nickel(Ⅱ) complex is more cytotoxic than cisplatin against MCF-7 cell line and shows higher growth inhibitory rates against MCF-7 and SKOV-3 cell lines than the corresponding thiosemicarbazone ligand alone. CCDC: 974828. | |
| Keywords: nickel(Ⅱ) complex thiosemicarbazone DNA interaction cytotoxicity | |
| 投稿时间：2013-12-16 修订日期：2014-04-13 | |
| 摘要点击次数: 2169 | |
| 全文下载次数: 1449 | |
| 闵睿,范晓瑞,周攀,颜军,周建良,张寿春.缩氨基硫脲Ni（Ⅱ）配合物的合成、晶体结构、DNA相互作用及抗肿瘤活性研究[J].无机化学学报,2014,30(8):1771-1777. | |
| 查看全文 查看/发表评论 下载PDF阅读器 | |
| Support information: | |
|
| |
|
| |
|
| |